The U.S. Food and Drug Administration (FDA) has approved a new drug Venclexta (venetoclax) for use in CLL patients with the 17p deletion. Andrew Schorr interviewed CLL expert Dr. Thomas Kipps to get his perspective on what this new approval means for patients.
Breaking News: Expert Perspective on V... - CLL America Support
Breaking News: Expert Perspective on Venclexta (venetoclax) Approval
Written by
mcints
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
obinutuzumab + venetoclax
Scheduled to start treatment end of the month to have CLL under control.
Felt fine otherwise and...
